Angiogenesis is the growth of blood vessels from a pre-existing vessel bed. Clinical interest in the control of angiogenesis arises from two distinct quarters. In one case, the goal is to block the growth of new vessels as a means to suppress and/or regress tumor growth, or to suppress vessel proliferation in pathologies such as diabetes. In the second case, the objective is to induce or stimulate vessel growth in patients with conditions characterized by insufficient blood flow, such as ischemic heart disease and peripheral vascular diseases. The latter applications are the focus of this review. We discuss some of the recent efforts to induce new vessel growth and we highlight challenges that have arisen regarding the means of delivery and efficacy of angiogenesis induction.

Angiogenic stimuli
==================

Both basic fibroblast growth factor (FGF-2) and vascular endothelial growth factor (VEGF)-A have been used in attempts to stimulate angiogenesis.

Fibroblast growth factor
------------------------

The fibroblast growth factor (FGF) family consists of an ever-increasing number of peptide growth factors with diverse cellular targets and biological effects \[[@B1]\]. Two family members, acidic fibroblast growth factor (FGF-1) and FGF-2, have a strong affinity for heparin and have been studied for their effects on vascular cells, including endothelial cells and smooth muscle cells. Extensive evidence indicates that both FGF-1 and FGF-2 are potent angiogenic factors, providing support for their use as stimuli for therapeutic angiogenesis *in vivo*. It is also important to note that many cell types express one of the four FGF receptors, and that FGF has been shown to have biological effects in a number of cell systems including induction of neurite outgrowth, suppression of skeletal muscle differentiation, induction of bone formation and neuroprotection, to name just a few.

Vascular endothelial growth factor-A
------------------------------------

VEGF-A is the prototypic member of a family of secreted, homodimeric glycoproteins with endothelial cell-specific mitogenic activity and the ability to stimulate angiogenesis *in vivo* \[[@B2]\]. VEGF-A also increases vascular permeability, with an effect 10,000 times more potent than that of the vasoactive substance histamine; VEGF-A was originally purified based on this property, and was named vascular permeability factor \[[@B3]\]. The VEGF-A family of polypeptides consists of a number of biochemically distinct isoforms (three isoforms in the mouse and up to five in humans) that are generated through alternative mRNA splicing of a single gene \[[@B4],[@B5]\]. The isoforms are named by the number of amino acids that comprise the proteins; the human isoforms include VEGF121, VEGF145, VEGF165, VEGF189, and VEGF206.

Preclinical studies
===================

Current clinical trials of angiogenesis factors were preceded by a large number of studies using animal models of cardiac or peripheral ischemia. Early studies involved protein administration, whereas later efforts began to employ gene therapy. In one early study using recombinant protein, a single intra-arterial injection of 500--1000 μg VEGF165 into rabbits with severe experimental hind limb ischemia increased collateral vessels, as detected by angiography and histological analysis \[[@B6]\]. Naked plasmid DNA injected directly into the skeletal muscle in a later study, using the same hind limb ischemia model, also yielded increased collateral vessels, as determined by angiography and improved perfusion \[[@B7]\].

Although such reports of increased vessel growth and functional improvement in response to exogenously administered angiogenic factors are encouraging, it is essential to note that animal models such as the ischemic hind limb model have definite limitations. Whereas the ischemia in the animal models is acute (produced by surgical procedure), the ischemia that characterizes the human disease often arises over an extended time and occurs in the context of complex atherosclerotic processes. The responses seen in the experimental models may thus be quite different in terms of the kinetics of vessel growth as well as the nature of the resultant vessels.

In a study assessing the effects of VEGF-A on myocardial ischemia in a porcine model of progressive coronary artery occlusion, VEGF-A was delivered by osmotic pump and magnetic resonance mapping revealed a reduction in the size of the ischemic zone and improved cardiac function \[[@B8]\]. A single bolus injection was also found to produce significant improvements in myocardial blood flow and function \[[@B9]\]. Myocardial ischemia in animals has also been treated with FGF. Delivery of FGF-2 via implantation of heparin-alginate beads led to an 80% reduction in infarct size and improved cardiac function in pigs with experimentally induced coronary artery constrictions, as compared with untreated controls \[[@B10]\]. These studies were followed closely by the demonstration of gene therapy in a porcine model of stress-induced myocardial ischemia. Intracoronary injection of a recombinant adenovirus expressing another member of the FGF family, human FGF-5, led to improvements in stress-induced function and blood flow that were maintained for 12 weeks \[[@B11]\].

Clinical trials
===============

Results from basic research have proven that both VEGF-A and FGF-2 are potent angiogenic factors, and the use of these factors in animal models has indicated that they have therapeutic potential. The two factors have therefore been entered into clinical trials, testing their ability to provide angiogenesis therapy for various diseases in which new vessel growth is desirable. Both VEGF-A and FGF-2 have been tested in phase I clinical trials, with mixed results \[[@B12],[@B13]\]. Although phase I trials are not designed to test efficacy, many important insights regarding the potential obstacles to using angiogenic therapies have become evident.

Fibroblast growth factor
------------------------

In one study, human recombinant FGF-2 was administered intraoperatively to areas of the coronary artery in 20 patients who were undergoing surgical revascularization \[[@B14]\]. Angiographic analysis revealed evidence of collateralization. Local sustained release of high dose (but not low dose) FGF-2 to ischemic areas, in 24 patients during bypass surgery, led to a reduction in stress defect size \[[@B15]\]. In a recent study involving 59 patients with coronary disease, the response to intravenous or intracoronary human recombinant FGF-2 was monitored by single photon emission computed tomography (SPECT) imaging \[[@B16]\]. Perfusion was monitored at approximately 1, 2, and 3 months after growth factor administration. Analysis of global stress perfusion or inducible ischemia revealed a consistent and sustained reduction in the extent and severity of stress-inducible ischemia, as well as an improvement in resting perfusion in areas where there was a risk of ischemia.

Vascular endothelial growth factor
----------------------------------

In an early phase I trial to test the safety and bioactivity of VEGF-A, naked VEGF165 DNA was injected into the myocardium of five patients who had failed standard therapy. SPECT imaging demonstrated reduced ischemia \[[@B17]\]. Adenoviral delivery of VEGF121 to the myocardium of 21 patients by direct injection, either as an adjunct to coronary bypass grafting or as the sole therapy, led to improvement in the area injected, as measured by angiography; angina was also reduced \[[@B18]\]. Administration of recombinant VEGF121 improved function, as detected by SPECT \[[@B19]\]. Furthermore, this study revealed a dose-dependent improvement in both stress perfusion and rest perfusion; there was an infrequent response in patients who received low dose VEGF and an improvement in five out of six patients who received high dose VEGF. In a different approach, VEGF cDNA was delivered via liposomes by catheter to coronary arteries following angioplasty \[[@B20]\]. While this phase I safety trial did not show an effect of VEGF-A on the degree of coronary ischemia, it did prove that the treatment was well tolerated.

It is important to note that no phase II controlled studies using defined and quantifiable endpoints have demonstrated efficacy of therapeutic angiogenesis. This highlights the main obstacles for assessing a therapeutic response to angiogenesis therapy, the reliability of the assessment methods and the possible complications of the placebo effect. There is thus a critical need for more controlled trials and for the development of better defined and more quantifiable endpoints.

Modes of delivery
=================

Delivery strategy is one of the most important variables when using angiogenic factors to treat pathological conditions. Expression of VEGF-A is tightly controlled during development, and slight changes in VEGF-A protein levels are associated with developmental abnormalities and embryonic lethality \[[@B21],[@B22]\]. Additionally, the unregulated expression of VEGF-A in the myocardium has been reported to produce deleterious cardiac effects in an animal model, causing cardiac failure and death \[[@B23]\]. Clearly, if VEGF-A is to be used for therapeutic angiogenesis, tight control of its levels must be achieved.

Protein therapy
---------------

At present, the administration of protein seems to be preferable to gene therapy \[[@B12]\]. This is mainly because dosage modulation in most clinical settings is far easier with purified protein than with gene therapy, which is hampered by the lack of a regulable expression vector. Although protein therapy has many advantages, there are nevertheless technical problems associated with protein administration, including optimization of purification and formulation of delivery for single and/or multiple angiogenic factors.

Recent advances in drug delivery methods using bioerodible polymer matrices will allow long-term sustained release of the growth factors \[[@B24]\]. This will resolve one of the major problems associated with protein administration; namely, the limited tissue half-life of the purified angiogenic factors in patients. An important consideration, however, is that protein therapy is limited to secreted factors. Delivery of intracellular modulators for therapeutic angiogenesis, including transcription factors that control angiogenesis such as hypoxia inducible factor-1 alpha (HIF-1α), is only possible through gene therapy.

Gene therapy
------------

Viral vectors have been the most commonly used means of gene delivery for both VEGF-A and FGF-2. Gene therapy presents an attractive alternative to purified proteins because it offers the possibility of sustained production of one or more factors following a single administration. Furthermore, tissue-specific and highly localized production of the therapeutic factor is possible, through the use of tissue-specific promoters.

However, a variety of issues have implications for the use of viral vectors in gene therapy. Obvious potential concerns are the immune and inflammatory responses to viral vectors. Patients who received VEGF121 via an adenoviral vector had increased levels of serum anti-adenoviral neutralizing antibodies, but there was no report on an inflammatory response in these patients \[[@B19]\]. The use of adenovirus-mediated gene therapy in treating brain tumors has been reported to lead to active brain inflammation as well as persistent (up to 3 months after treatment) transgene expression \[[@B25]\].

The lack of regulable gene expression is another potential barrier. Some systems for inducible gene expressions have proved to be effective and safe in animal models \[[@B26]\], but have not yet been tested in humans. Recent advances in stem cell research provide the possibility of combining gene therapy with *ex vivo* gene transfer into stem cells for angiogenesis therapy, as will be discussed later. If successful, this approach may overcome most of the obstacles presented by gene therapy.

Considerations for the future
=============================

Interpatient variability
------------------------

It is not clear why some individuals develop a collateral circulation sufficient to compensate for their ischemic vascular disease whereas others do not. Certainly, features such as the extent of the disease and the time frame over which the ischemia develops are contributing factors. However, other previously unconsidered variables appear to play important roles.

Collateral vessel development, as measured by blood pressure, angiography, and vessel density, was significantly reduced in old (4--5 years old) versus young (6--8 months old) animals \[[@B27]\], in a rabbit model of hind limb ischemia. Endothelial cell dysfunction and reduced VEGF-A levels were the reasons suggested for the reduced collateral response. A subsequent study, demonstrating an age-dependent reduction in HIF-1α activity, provides one explanation for the lower VEGF-A expression in response to hypoxia in aged animals \[[@B28]\]. A reduced response to hypoxia might translate into a weaker angiogenic response. This is supported by the fact that the extent of hypoxic induction of VEGF-A in monocytes correlates strongly with the presence of collateral vessels in patients \[[@B29]\].

It is possible that genetic variability may also play a significant role in an individual\'s ability to generate collateral vessels in response to ischemia, as well as their capacity to respond to an exogenous angiogenic agent. Not surprisingly, a recent report that assessed the angiogenic response in a murine corneal pocket model to a fixed dosage of FGF-2 in various strains of mice suggested that genetic backgrounds may influence angiogenic response \[[@B30]\]. A nearly 10-fold range of response to the fixed dosage of FGF-2 was observed among different inbred strains of mice, suggesting that genetic variability may indeed play a significant role in determining the magnitude of angiogenic response to FGF-2.

Systemic effects
----------------

If VEGF-A delivery leads to significant circulating levels, as has been observed following myocardial transfection with VEGF-A cDNA \[[@B31]\], then it may possibly affect angiogenesis elsewhere \[[@B32]\]. As plaque progression might be dependent on angiogenesis \[[@B33]\], investigators were prompted to examine the effect of VEGF-A administration on this process. Mice that were double deficient in apolipoprotein E and apolipoprotein β 100 were treated with a single intraperitoneal injection of VEGF165 recombinant human protein (2 μg/kg). This led to significant increases in plaque area compared with untreated controls \[[@B34]\]. In contrast, there has been no evidence of disease progression, to date, in 42 patients treated with intra-arterial gene transfer of naked VEGF-A cDNA. This has been delivered either to promote therapeutic angiogenesis (12 patients) or to accelerate re-endothelization (30 patients) \[[@B35]\]. Although these observations suggest that human sensitivity to VEGF-A may be lower than in animal models, it will be necessary to study a larger cohort of patients, with appropriate controls, over a longer time period to confirm this \[[@B36]\].

VEGF has also been shown to mediate the vessel growth that characterizes tumor expansion as well as the neovascularization that is associated with diabetic retinopathy. Although VEGF is produced locally in both of these circumstances, it is not known whether systemic administration of the factor could exacerbate these conditions by further stimulating vessel growth. Selection of the patient population that may benefit from angiogenic therapy may thus have to involve screening for coexisting conditions that could be activated or worsened by exposure to proangiogenic agents.

VEGF-A, FGF-1, and FGF-2 have all demonstrated systemic vascular effects. FGF-1 and FGF-2 have been shown to reduce blood pressure in a dose-dependent manner in rats \[[@B37]\]. Similarly, VEGF-A has been reported to cause hypotension and death in pigs following an intracoronary bolus administration \[[@B38]\]. Subsequent studies have revealed that VEGF-A administration causes greater vasodilatation of coronary vessels than serotonin or nitroglycerin, and also causes tachyphylaxis via a nitric oxide-dependent mechanism \[[@B39]\]. VEGF-A administration to the extremities of patients has also been associated with hypotension and edema \[[@B40]\]. These side effects can be partly explained by the fact that VEGF-A is a potent vascular permeability factor.

VEGF-A isoforms in angiogenesis therapy
---------------------------------------

The five VEGF-A protein isoforms in humans (and at least three major isoforms in the mouse) have different biochemical and biological properties \[[@B41]\]. It is therefore important to determine whether different VEGF-A isoforms give rise to different quality or quantity of vessels. Expression of the various isoforms during development is modulated both spatially and temporally \[[@B42]\], and observations from gene knockout studies have proven that these isoforms do not have equivalent biological functions during vessel development \[[@B42],[@B43]\]. Furthermore, there is considerable variability in the phenotype of vessels in tumors expressing different isoforms \[[@B44]\]. For example, vessels within tumors expressing predominantly the VEGF189 isoform, which has a strong heparin-binding affinity and thus is highly localized, are much less leaky than the vessels in tumors expressing the more diffusible VEGF165 and VEGF121 isoforms \[[@B45]\]. It will be interesting and important to determine whether these observations from experimental systems can help predict the results of clinical trials, which primarily employ the VEGF165 isoform. Finally, since multiple VEGF-A isoforms are expressed during vascular development \[[@B42]\], it will also be important to determine whether the use of multiple isoforms in angiogenesis therapy will be necessary to replicate *in vivo* conditions.

Achieving vessel stability
==========================

The induction of new vessels to supply ischemic tissues is the primary goal of angiogenic therapy. Reaching this objective is, however, highly complex. Vessels formed in response to artificial angiogenic stimuli are prone to regression unless they are remodeled into mature, stable vessels \[[@B46]\]. Thus, as the level of knowledge regarding the mechanisms of vessel growth and stabilization increases, there is increasing concern that the simple application of a bolus of angiogenic factor may be insufficient for stable vessel formation, or may even be dangerous.

Early studies involving the administration of VEGF-A showed angiographic evidence of new vessel formation, but these vessels did not persist and they regressed within 3 months \[[@B40]\]. It was recently reported that continuous delivery of VEGF-A into murine hearts by retroviral transfer led to the formation of aberrant vessels and hemangioma-like structures \[[@B23]\]. One of the major problems encountered in the use of VEGF-A is that vessels formed are unstable and leaky \[[@B47]\]. It has been speculated that VEGF-A alone may not be sufficient to form stable, mature vessels that are characterized by the recruitment of the perivascular mural cells, such as pericytes or smooth muscle cells \[[@B48]\]. This process of vessel maturation is called arteriogenesis and is arguably the ideal way to form stable vessels for therapeutic purposes \[[@B49]\].

Administration of multiple factors
==================================

Various growth factors such as angiopoietin (ang)-1, platelet-derived growth factor, transforming growth factor-β as well as VEGF-A are also involved in arteriogenesis, and it may therefore be necessary to use combinations of these factors to obtain stable and mature vessels (Fig. [1](#F1){ref-type="fig"}). Indeed, when VEGF-A and ang-1 are administered together in animal models, the resulting vessels are much more stable and less leaky than those that are induced by VEGF-A alone \[[@B50]\]. Similarly, administration of submaximal doses of ang-1 and VEGF-A in a rabbit ischemic hind limb model led to a stronger effect on resting and maximal blood flow and capillary formation than either of the agents alone \[[@B51]\].

![Assembly of a stable vessel. Local increases in angiogenic factors such as fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) during new vessel formation destabilize a portion of an existing vessel (usually a venule). Destabilization is associated with increased angiopoietin (ang)-2 expression and with pericyte activation, matrix remodeling, and induction of pericyte and endothelial cell (EC) migration and proliferation. Newly formed vessels may be dependent on exogenous factors for their survival until they have been remodeled to mature structures. Remodeling involves EC recruitment of pericyte/smooth muscle cell (SMC) precursors via endothelial-derived platelet-derived growth factor (PDGF). Once the mural cell precursor makes contact with the vessel, transforming growth factor (TGF)-β is activated, which in turn suppresses the proliferation and migration and induces the differentiation into SMC/pericytes. In addition to TGF-β, ang-1 produced by the SMC/pericytes is also involved in the stabilization and maintenance of the stable mature vessel. aFGF, acidic fibroblast growth factor; bFGF, basic fibroblast growth factor; CEP, circulating endothelial precursor.](cvm-2-6-278-1){#F1}

Using a master switch gene
==========================

Another approach that addresses the involvement of multiple factors in therapeutic angiogenesis is the use of a so-called \'master switch gene\' of angiogenesis, such as HIF-1α \[[@B52]\]. This transcription factor can activate a collection of different genes that are involved in angiogenesis, including those encoding VEGF-A, VEGF receptor 1 (Flt-1), and ang-2 \[[@B53],[@B54]\]. It is hoped that using a \'master switch gene\' will result in more stable vessels, because the processes by which they are formed would resemble more closely those of normal vessel development.

Stem cells in therapeutic angiogenesis
======================================

The existence of circulating endothelial precursor (CEP) cells in adults has been reported \[[@B55],[@B56]\]. It has also been demonstrated that similar precursor cells may give rise to both endothelial cells and perivascular mural cells \[[@B57]\]. Furthermore, in an *in vitro* model of angiogenesis, normal vascular development has been shown to require the presence of the CD45^+^/c-Kit^+^/CD34^+^ hematopoietic stem cells \[[@B58]\], which are similar and may be related to adult CEP cells.

It has been reported that CEP cells are able to participate in new vessel growth in a variety of animal models, including the rabbit ischemic hind limb model \[[@B59]\]. In patients with inoperable coronary disease, increased circulating VEGF-A resulting from transfection of myocardium with VEGF165 cDNA led to a significant mobilization of CEP cells \[[@B31]\]. Another recent publication has shown that granulocyte-colony stimulating factor mobilized CD34^+^ cells, including endothelial cell precursors with phenotypic and functional characteristics of embryonic angioblasts \[[@B60]\]. When injected into rats with experimental myocardial infarction, these CD34^+^ cells contributed to new vessel growth, which led to decreased cardiomyocyte apoptosis, to reduced remodeling, and to improved cardiac function.

Further studies of how CEP cells are released from bone marrow and to what extent they participate in postnatal angiogenesis will certainly provide valuable information regarding the therapeutic potential of CEP cells. The possibility of using CEP cells, both alone and in combination with different angiogenic growth factors, represents a promising means of obtaining stable vessels. Finally, since the use of CEP cells would allow easy *ex vivo* gene transfer, combining growth factor-induced therapeutic angiogenesis with gene therapy delivered via CEP should also be a promising approach.

Conclusion
==========

As research into therapeutic angiogenesis progresses, new information regarding the control of vessel remodeling and stability will be incorporated into treatment strategies. Better designed studies and clinical trials that consider the issues discussed, coupled with well-defined and quantitative endpoints, will facilitate the development of novel and effective therapeutic approaches for ischemic diseases.
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